Bevacizumab

Title Average Ratingsort ascending
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. 90.00%
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients .... 80.00%
Bevacizumab for recurrent ependymoma. 80.00%
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. 80.00%
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. 80.00%
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. 80.00%
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). 70.00%
Dose-Dense and/or Metronomic Schedules of Specific Chemotherapies Consolidate the Chemosensitivity of Triple-Negative Breast Can 63.33%
Hypoxia-inducible factor-1alpha modulation in combination with anti-angiogenic therapy. 60.00%
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symp 60.00%
Anti-angiogenic therapies for metastatic colorectal cancer. 60.00%
Complete remission of psoriasis following bevacizumab therapy for colon cancer. 60.00%
Tumoral angiogenesis: review of the literature. 50.00%
Novel anti-angiogenic therapies for malignant gliomas. 50.00%
Chemoradiotherapy in malignant glioma: standard of care and future directions. 50.00%
Lessons learned in the development of targeted therapy for malignant gliomas 50.00%
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. 50.00%
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. 50.00%
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal 50.00%
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab.... 40.00%
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplat 40.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. 0.00%